Biotinylated Human Fc gamma RI / CD64 Protein, His,Avitag™ (SPR & BLI & MALS verified)
分子别名（Synonym）
FCGR1A,FCG1,FCGR1,IGFR1,CD64,CD64A,FCRI
表达区间及表达系统（Source）
Biotinylated Human CD64, His,Avitag (FCA-H82E8) is expressed from human 293 cells (HEK293). It contains AA Gln 16 - Pro 288 (Accession # P12314-1).
Predicted N-terminus: Gln 16
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 34.2 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记（Labeling）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
纯度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
背景介绍
识别IgG Fc片段的受体分为三类：高亲和力FcγRI（CD64）、低亲和力FcγRII（CD32）与FcγRIII（CD16）。FcγRI在免疫应答早期通过高亲和力结合单体IgG发挥作用；FcγRII和FcγRIII则作为低亲和力受体，在免疫应答后期识别多价抗原周围的IgG聚集体。
高亲和力免疫球蛋白γFc受体I（FCGR1A/CD64）又称FCG1/FCGR1/IGFR1，属免疫球蛋白超家族成员，是能高亲和力结合单体IgG抗体的整合膜糖蛋白。该受体含3个C2型免疫球蛋白样结构域，常态下仅表达于巨噬细胞和单核细胞表面，而干扰素γ（IFNγ）或粒细胞集落刺激因子（G-CSF）等细胞因子可诱导粒细胞表达CD64。
关键字： Fc gamma RI / CD64;FCGR1A蛋白;CD64重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。